Callan Family Office LLC Purchases 48,269 Shares of Pfizer Inc. $PFE

Key Points

• Callan Family Office LLC increased its holdings in Pfizer Inc. by 230.6% during the second quarter, acquiring an additional 48,269 shares for a total of 69,203 shares worth $1,677,000.
• Several hedge funds, including Vanguard Group Inc. and Northern Trust Corp, have also recently modified their positions in Pfizer, with institutional investors owning 68.36% of the company's stock.
• Pfizer recently announced a quarterly dividend of $0.43 per share, representing a 6.9% dividend yield, with the payout ratio currently at 91.49%.

Callan Family Office LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 230.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,203 shares of the biopharmaceutical company's stock after acquiring an additional 48,269 shares during the period. Callan Family Office LLC's holdings in Pfizer were worth $1,677,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Vanguard Group Inc. boosted its holdings in shares of Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the period. Northern Trust Corp boosted its holdings in shares of Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after buying an additional 3,943,397 shares during the period. Amundi boosted its holdings in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the period. Invesco Ltd. boosted its holdings in shares of Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after buying an additional 838,198 shares during the period. Finally, Deutsche Bank AG boosted its holdings in shares of Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after buying an additional 1,846,436 shares during the period. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday. UBS Group reiterated a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $28.35.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.81 on Friday. The firm has a 50 day moving average of $24.86 and a 200-day moving average of $24.13. The stock has a market capitalization of $141.03 billion, a PE ratio of 13.19, a PEG ratio of 0.81 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.